CYP3A4 and breast cancer: For some oral neoadjuvant chemotherapy drugs for breast cancer, exposure to CYP3A after administration is almost inevitable, and the catalytic reaction mediated by CYP3A strongly limits the oral bioavailability of the drug, which usually leads to drug inactivation [10,11].